Core Insights - NRx Pharmaceuticals and neurocare Group AG have formed a partnership to establish a nationwide network of clinics for integrated neuroplastic care targeting Depression, PTSD, and other serious mental health disorders [1][4] Group 1: Partnership and Objectives - The partnership aims to combine Transcranial Magnetic Stimulation (TMS) with ketamine and other neuroplastic drugs, alongside hyperbaric oxygen therapy and psychotherapy, to improve treatment outcomes for First Responders suffering from PTSD and Depression [1][2] - The goal is to provide innovative neuroplastic therapy accessible within driving distance for all Americans by the end of 2026, addressing the needs of over 50 million individuals in the US and 500 million globally affected by these conditions [4][5] Group 2: Clinical Efficacy and Research - Recent studies indicate that the integration of TMS with neuroplastic drugs has achieved an 87% response rate and a 72% remission rate in patients with treatment-resistant depression, although further research is needed [2][6] - Pilot programs have shown high success rates in combining TMS, neuroplastic drug treatment, hyperbaric oxygen, and psychotherapy for First Responders [6] Group 3: Existing Infrastructure and Future Plans - The partnership will utilize the existing network of 20 neurocare clinics and over 400 Apollo TMS devices across the US to facilitate the integrated treatment program [4][6] - The collaboration seeks to create a standardized approach to treatment protocols and clinical training, leveraging neurocare's expertise in neuromodulation technology and NRx's neuroplastic drug development [3][6] Group 4: Company Backgrounds - neurocare Group AG has developed a platform for neuroplastic therapy, including the Apollo TMS device, and operates over 40 clinics internationally, with annual sales exceeding €35 million in 2025 and projected to exceed €50 million in 2026 [8] - NRx Pharmaceuticals is focused on developing therapeutics for central nervous system disorders, with products like NRX-100 and NRX-101 targeting suicidal depression and bipolar depression, respectively [9][10]

Core Insights - NRx Pharmaceuticals has amended its Investigational New Drug filing for NRX-101 to include its use in conjunction with Transcranial Magnetic Stimulation (TMS) for treating depression, including suicidal depression [1][8] Group 1: Clinical Findings - NRX-101 has shown a promising new indication that may expedite its commercialization as a Breakthrough Therapy-designated drug, with evidence indicating a more than two-fold benefit in symptom reduction when combined with TMS [2] - Clinical trials reported a 75% clinical response and a 40% remission rate in patients treated with D-cycloserine (DCS) alongside TMS [2] - A recent study using a modern TMS device and a one-day protocol combined with DCS showed an 87% clinical response and a 72% remission rate at six weeks [3] Group 2: Mechanism and Efficacy - Nonclinical evidence suggests that D-cycloserine enhances neuroplasticity when used with TMS, potentially leading to a response rate exceeding 80%, which is significantly higher than the 30% success rate associated with traditional SSRI antidepressants [4] - NRX-101 combines D-cycloserine with a low dose of lurasidone, which is already approved for depression treatment and has anti-hallucinatory properties, addressing the contraindication of DCS in depression patients [5] Group 3: Future Prospects - The company plans to conduct well-controlled trials with approximately 120 participants to further validate the clinical benefits observed in earlier studies [6] - NRx anticipates that over 1 million Americans may be treated with TMS annually by 2030, creating a substantial market opportunity for NRX-101 [7] - The company has published an Expanded Access policy for NRX-101, allowing physicians to request information for patients who may benefit from the treatment [7]

Core Insights - HOPE Therapeutics, Inc. has acquired a strategic interest in Cohen and Associates, LLC, integrating it into the HOPE Network, with Dr. Rebecca Cohen appointed as Medical Director overseeing care standards in Florida [1][9] Company Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focusing on building a network of interventional psychiatry clinics offering treatments such as ketamine and Transcranial Magnetic Stimulation (TMS) for patients with suicidal depression and related disorders [7] - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD, with products like NRX-100 and NRX-101 [6] Leadership and Expertise - Dr. Rebecca Cohen is a recognized expert in TMS and has a strong academic background, having founded her practice in 2014 as one of the first dedicated interventional psychiatry practices in the U.S. [3][9] - The leadership team at HOPE, including Dr. Cohen and Stephen Durand, RN, aims to advance interventional psychiatry and expand treatment options for patients [4][5] Strategic Goals - The acquisition of Cohen, LLC is expected to enhance HOPE Therapeutics' revenue and EBITDA, with immediate expansion plans in Western Florida and Palm Beach [9]

Core Insights - NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025 [1][2] - The presentation will include a corporate update and plans to launch a low-dose D-Cycloserine product, which has shown to more than double the effectiveness of Transcranial Magnetic Stimulation in treating depression [2] - NRx Pharmaceuticals is actively involved in treating veterans with suicidal depression and PTSD, collaborating with the US Department of Veterans Affairs [2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [4] - The company is developing NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation and NRX-101 receiving Breakthrough Therapy Designation for treating suicidal bipolar depression [4] - NRx has recently re-filed an Abbreviated New Drug Application for NRX-100 and initiated a New Drug Application filing for the treatment of suicidal ideation in patients with depression [4] HOPE Therapeutics Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focused on building a network of interventional psychiatry clinics [5] - The clinics will offer treatments such as ketamine, Transcranial Magnetic Stimulation, and Hyperbaric Oxygen Therapy for patients with suicidal depression and related disorders [5] - HOPE Therapeutics aims to enhance the clinical benefits of NMDA-targeted drug therapy through a digital therapeutic-enabled platform [5]

Core Insights - HOPE Therapeutics, Inc. has received final clearance from the Florida Agency for Health Care Administration to close the acquisition of Dura Medical LLC, which is a revenue-generating and EBITDA positive entity [1][8] - Dura Medical specializes in precision treatment for mental health and chronic pain, utilizing advanced interventional psychiatry procedures [2][8] - The acquisition is expected to enhance HOPE's revenue and EBITDA, contributing to its expansion in Florida and beyond [5][8] Company Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focusing on building a network of interventional psychiatry clinics that provide treatments such as ketamine therapy and Transcranial Magnetic Stimulation (TMS) [9] - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression and PTSD [6] Dura Medical's Mission and Services - Dura Medical aims to reduce suicide rates in the community, with a goal to treat over 10,000 individuals by 2026 [4] - The clinic offers a comprehensive range of services, including Ketamine Infusion Therapy, TMS, and Spravato®, targeting conditions like depression, PTSD, and anxiety [2][3] Regulatory and Strategic Developments - The acquisition of Dura Medical is part of a broader strategy that includes previous acquisitions aimed at expanding coverage along the West Coast of Florida [8] - The intended closing of the acquisition is subject to standard closing conditions, indicating a structured approach to regulatory compliance [5][8]

Core Insights - BrainsWay is launching two new Continuing Medical Education (CME) courses to enhance clinician knowledge and confidence in Transcranial Magnetic Stimulation (TMS) [1][2] - The courses are designed to clarify the differences between BrainsWay's Deep TMS™ technology and first-generation TMS, while providing practical guidance for clinical integration [1][3] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, focusing on its proprietary Deep TMS™ platform technology [5] - The company has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies [5] - BrainsWay aims to increase global awareness and access to Deep TMS, with ongoing clinical trials for various psychiatric, neurological, and addiction disorders [5] Educational Initiatives - The CME courses are supported by independent educational grants from BrainsWay and offer up to 0.5 AMA PRA Category 1 Credits™ [2] - The courses are accessible online to a wide range of healthcare professionals, including psychiatrists and nurse practitioners [2] - The first course focuses on evidence-based data supporting TMS and its role in mental health treatment, while the second course emphasizes practical strategies for patient identification and treatment integration [6]

Core Viewpoint - HOPE Therapeutics, Inc. has signed a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC, a leading Interventional Psychiatry clinic in Florida, which is expected to enhance HOPE's clinical care capabilities in the region [1][2][8]. Company Overview - HOPE Therapeutics, Inc. is a subsidiary of NRx Pharmaceuticals, focused on building a network of interventional psychiatry clinics to provide treatments for suicidal depression and related disorders [8][9]. - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression and PTSD [6]. Acquisition Details - The acquisition of Cohen is anticipated to be immediately accretive to revenue and EBITDA for HOPE Therapeutics [8]. - The transaction is subject to the execution of definitive documents and standard closing requirements, with further details to be disclosed later [5]. Cohen and Associates - Cohen and Associates, founded by Dr. Rebecca Cohen, is recognized for its comprehensive treatment options for suicidal depression, PTSD, and other CNS disorders, including ketamine and Transcranial Magnetic Stimulation (TMS) [2][3]. - Dr. Rebecca Cohen is an expert in mood and anxiety disorders, with a strong academic background and recognition in the field of TMS [3]. Leadership Statements - The leadership of HOPE Therapeutics expressed enthusiasm about the acquisition, highlighting Dr. Cohen's experience and commitment to patient care as a perfect fit for the company's mission [4][5].

Core Viewpoint - HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Dura Medical, enhancing its interventional psychiatry network on Florida's west coast, with Dura being revenue-generating and EBITDA positive [1][9]. Company Overview - HOPE Therapeutics is focused on developing a network of interventional psychiatry clinics that utilize psychedelic medications, including ketamine and Spravato®, combined with Transcranial Magnetic Stimulation (TMS) and other therapies for patients with suicidal depression and related disorders [7]. - NRx Pharmaceuticals, the parent company of HOPE, is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain [8]. Acquisition Details - Dura Medical, founded in 2018, specializes in a precision approach to treating mental health and chronic pain, offering services such as Ketamine Infusion Therapy and TMS [2][9]. - The acquisition is expected to provide comprehensive services to patients and is part of HOPE's strategy to expand its operations in Florida [1][9]. - The intended closing of the acquisition is subject to financial audits, regulatory approvals, and standard closing conditions [6]. Leadership and Mission - Stephen Durand, the founder of Dura Medical, will serve as the Director of Florida Clinic Operations for HOPE, emphasizing the mission to reduce suicide rates and treat over 10,000 individuals by 2026 [4][3]. - The collaboration aims to integrate Dura's commitment to patient care for both civilians and veterans into HOPE's network [5][9]. Services Offered - Dura Medical provides a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and TMS, catering to both veteran and civilian patients [9]. - The clinics utilize advanced interventional psychiatry procedures to address various mental health issues, including depression, suicidality, PTSD, and anxiety [2]. Future Plans - HOPE Therapeutics plans to expand its service offerings and enhance its operational capabilities through the acquisition of Dura Medical and the previously announced Neurospa network [1][9]. - The company is also pursuing the development of NRX-101, an investigational therapy for suicidal treatment-resistant bipolar depression, with plans to file for Accelerated Approval [8][10].